Wegovy Gets the OK from FDA for a MASH Indication
August 16, 2025 — Late yesterday FDA granted Wegovy (semaglutide 2.4 mg) a big new indication – treatment of MASH. The indication FDA approved reads as follows: “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. “The indication […]
